Overview

A Study of Selinexor in Combination With Azacitidine and Venetoclax (SAV Regimen) in Treatment Naïve Participants With Acute Myeloid Leukemia

Status:
Not yet recruiting

Trial end date:
2027-04-30

Target enrollment:

Participant gender:

Summary

This is a prospective, single-arm, multi-center clinical trial to evaluate the efficacy and safety of selinexor in combination with azacitidine and venetoclax for untreated acute myeloid leukemia.

Phase:

Phase 2

Details

Lead Sponsor:

Shanghai Tong Ren Hospital

Treatments:

Azacitidine
Venetoclax